Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development

Lade...
Vorschaubild
Dateien
Marx_2-tqyy3cykvifs8.pdf
Marx_2-tqyy3cykvifs8.pdfGröße: 5.88 MBDownloads: 468
Datum
2020
Autor:innen
Marx, Uwe
Akabane, Takafumi
Andersson, Tommy B.
Baker, Elizabeth
Beilmann, Mario
Beken, Sonja
Brendler-Schwaab, Susanne
et al.
Herausgeber:innen
Kontakt
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
ArXiv-ID
Internationale Patentnummer
Link zur Lizenz
EU-Projektnummer
681002
DFG-Projektnummer
Projekt
EUToxRisk21
Open Access-Veröffentlichung
Sammlungen
Gesperrt bis
Titel in einer weiteren Sprache
Forschungsvorhaben
Organisationseinheiten
Zeitschriftenheft
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Alternatives to Animal Experimentation : ALTEX. Springer Spektrum. 2020, 37(3). ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.2001241
Zusammenfassung

The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all.

Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.

Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690MARX, Uwe, Takafumi AKABANE, Tommy B. ANDERSSON, Elizabeth BAKER, Mario BEILMANN, Sonja BEKEN, Susanne BRENDLER-SCHWAAB, Thomas HARTUNG, Marcel LEIST, Giorgia PALLOCCA, 2020. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. In: Alternatives to Animal Experimentation : ALTEX. Springer Spektrum. 2020, 37(3). ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.2001241
BibTex
@article{Marx2020Biolo-49035,
  year={2020},
  doi={10.14573/altex.2001241},
  title={Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development},
  number={3},
  volume={37},
  issn={1868-596X},
  journal={Alternatives to Animal Experimentation : ALTEX},
  author={Marx, Uwe and Akabane, Takafumi and Andersson, Tommy B. and Baker, Elizabeth and Beilmann, Mario and Beken, Sonja and Brendler-Schwaab, Susanne and Hartung, Thomas and Leist, Marcel and Pallocca, Giorgia}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/49035">
    <dc:creator>Baker, Elizabeth</dc:creator>
    <dc:contributor>Akabane, Takafumi</dc:contributor>
    <dc:contributor>Andersson, Tommy B.</dc:contributor>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/49035/1/Marx_2-tqyy3cykvifs8.pdf"/>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/49035/1/Marx_2-tqyy3cykvifs8.pdf"/>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:title>Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development</dcterms:title>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:contributor>Baker, Elizabeth</dc:contributor>
    <dc:contributor>Beilmann, Mario</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Beilmann, Mario</dc:creator>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:abstract xml:lang="eng">The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all.&lt;br /&gt;&lt;br /&gt;Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.</dcterms:abstract>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Beken, Sonja</dc:creator>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-03-13T11:52:59Z</dcterms:available>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Brendler-Schwaab, Susanne</dc:creator>
    <dc:language>eng</dc:language>
    <dc:contributor>Beken, Sonja</dc:contributor>
    <dc:creator>Akabane, Takafumi</dc:creator>
    <dc:creator>Andersson, Tommy B.</dc:creator>
    <dcterms:issued>2020</dcterms:issued>
    <dc:contributor>Pallocca, Giorgia</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Pallocca, Giorgia</dc:creator>
    <dc:creator>Marx, Uwe</dc:creator>
    <dc:contributor>Brendler-Schwaab, Susanne</dc:contributor>
    <dc:contributor>Marx, Uwe</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2020-03-13T11:52:59Z</dc:date>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/49035"/>
  </rdf:Description>
</rdf:RDF>
Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Kontakt
URL der Originalveröffentl.
Prüfdatum der URL
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja